KORU Medical CTO granted stock and options

KORU Medical Systems reported that its Chief Technology Officer, Eric Schiller, received new equity awards on January 2, 2026.

Rhea-AI Filing Summary

KORU Medical Systems reported that its Chief Technology Officer, Eric Schiller, received new equity awards on January 2, 2026. He was granted 76,426 shares of common stock at a price of $0, described as restricted stock issued as an employment inducement award that will vest 25% annually starting on January 2, 2027. He was also granted an option to buy 232,297 shares of common stock with an exercise price of $5.7 per share, with one-fourth of the option scheduled to vest on January 2, 2027 and on each of the first, second and third anniversaries of that date.

Insider Trade Summary

Grant/Award: 308,723 shares

Grant/Award 2 txns

Insider Schiller Eric

Role Chief Technology Officer

Type	Security	Shares	Price	Value
Grant/Award	Option to buy Common Stock	232,297	$0.00	$0.00
Grant/Award	Common Stock	76,426	$0.00	$0.00

Holdings After Transaction: Option to buy Common Stock — 232,297 contracts (Direct); Common Stock — 76,426 shares (Direct)

Footnotes (2)

1. F1. Represents shares of restricted stock issued as an employment inducement award that vest 25% annually commencing January 2, 2027, subject to acceleration as provided in his employment agreement.
2. F2. One-fourth will vest on January 2, 2027 and on each first, second and third anniversary thereof, subject to acceleration as provided in his employment agreement.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did KRMD report for its CTO?

KORU Medical Systems, Inc. reported that Chief Technology Officer Eric Schiller received new equity awards on January 2, 2026, including restricted stock and stock options.

How many KRMD common shares were granted to the CTO on January 2, 2026?

Eric Schiller was granted 76,426 shares of KRMD common stock at a grant price of $0, described as restricted stock issued as an employment inducement award.

What stock option grant did KRMD’s CTO receive according to the Form 4?

He received an option to buy 232,297 shares of KRMD common stock with an exercise price of $5.7 per share, reported as acquired on January 2, 2026.

How do the restricted KRMD shares granted to the CTO vest?

The 76,426 restricted shares vest 25% annually, commencing on January 2, 2027, with vesting subject to acceleration as provided in his employment agreement.

What is the vesting schedule for the KRMD stock options granted to the CTO?

For the 232,297 stock options, one-fourth will vest on January 2, 2027 and one-fourth on each of the first, second and third anniversaries of that date, subject to acceleration under his employment agreement.

Does the Form 4 indicate whether the CTO owns these KRMD awards directly or indirectly?

The Form 4 shows the 76,426 common shares and the 232,297 stock options as direct (D) ownership by Eric Schiller, with no separate entity listed for indirect ownership.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/15/2026 - 07:46 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Schiller Eric

(Last) (First) (Middle)

C/O KORU MEDICAL SYSTEMS, INC.

100 CORPORATE DRIVE

(Street)

MAHWAH NJ 07430

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
KORU Medical Systems, Inc. [ KRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/02/2026		A		76,426(1)	A	$0	76,426	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option to buy Common Stock	$5.7	01/02/2026		A		232,297		(2)	01/02/2026	Common Stock	232,297	$0	232,297	D

Explanation of Responses:

1. Represents shares of restricted stock issued as an employment inducement award that vest 25% annually commencing January 2, 2027, subject to acceleration as provided in his employment agreement.

2. One-fourth will vest on January 2, 2027 and on each first, second and third anniversary thereof, subject to acceleration as provided in his employment agreement.

Remarks:

The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person. Power of Attorney has been previously filed.

	/s/ Thomas Adams Attorney-In-Fact	01/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.